David Kirn
Founder chez 4D MOLECULAR THERAPEUTICS, INC.
Fortune : 34 M $ au 31/03/2024
Profil
David H.
Kirn was the founder of SillaJen Biotherapeutics, Inc. (founded in 2006) and 4D Molecular Therapeutics, Inc. (founded in 2013), where he holds the titles of President & Chief Medical Officer and Chief Executive Officer & Director, respectively.
Dr. Kirn is also the founder of Ignite Immunotherapy, Inc. Dr. Kirn's current jobs include Director at Coagulant Therapeutics, Inc. and Professor at the University of Oxford.
Dr. Kirn's former jobs include Principal at Warner-Lambert Co., Principal at Onyx Pharmaceuticals, Inc., Member at Harvard University, Faculty Member at The University of California, San Francisco, Advisor at National Institutes of Health, Principal at IP2IPO Innovations Ltd., and Faculty Member at Specialist Diabetes Research & Treatment Centre LLC.
Dr. Kirn obtained his undergraduate degree from the University of California, Berkeley in 1985 and his doctorate degree from The University of California, San Francisco in 1989.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/02/2024 | 1 059 153 ( 2,13% ) | 34 M $ | 31/03/2024 |
Postes actifs de David Kirn
| Sociétés | Poste | Début |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Founder | 12/09/2013 |
| University of Oxford | Corporate Officer/Principal | - |
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Director/Board Member | - |
Anciens postes connus de David Kirn
| Sociétés | Poste | Fin |
|---|---|---|
Ignite Immunotherapy, Inc.
 Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Part of Pfizer Inc., Ignite Immunotherapy, Inc. is a private company that designs and develops oncolytic virus vaccines. The company is based in New York, NY. The company was founded by David Schaffer, Douglas Hanahan, David H. Kirn, Theresa Janke, Melissa Kotterman. The CEO is Monika A. Vnuk. | Founder | 01/01/2019 |
Warner-Lambert Co.
 Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Corporate Officer/Principal | - |
Specialist Diabetes Research & Treatment Centre LLC
 Specialist Diabetes Research & Treatment Centre LLC Medical/Nursing ServicesHealth Services Specialist Diabetes Research & Treatment Centre LLC specializes in diabetes treatment, research, training and public health awareness. Its services include diabetes, endocrinology, bariatric & metabolic, antenatal, cardiology, nephrology, podiatry, ophthalmology, radiology, dietetic services, laboratory, and pharmacy. The company was founded in May 2006 and is headquartered Abu Dhabi, United Arab Emirates. | Corporate Officer/Principal | - |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Formation de David Kirn
| University of California, Berkeley | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Warner-Lambert Co.
Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
IP2IPO Innovations Ltd.
 IP2IPO Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services IP2IPO Innovations Ltd. provides business development and technology transfer services. The firm also provides strategic industry University partnerships, patenting, licensing, spin-out incubation and equity management services. The company was founded in 1986 and is headquartered in London, the United Kingdom. | Commercial Services |
Specialist Diabetes Research & Treatment Centre LLC
Specialist Diabetes Research & Treatment Centre LLC Medical/Nursing ServicesHealth Services Specialist Diabetes Research & Treatment Centre LLC specializes in diabetes treatment, research, training and public health awareness. Its services include diabetes, endocrinology, bariatric & metabolic, antenatal, cardiology, nephrology, podiatry, ophthalmology, radiology, dietetic services, laboratory, and pharmacy. The company was founded in May 2006 and is headquartered Abu Dhabi, United Arab Emirates. | Health Services |
Ignite Immunotherapy, Inc.
Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Part of Pfizer Inc., Ignite Immunotherapy, Inc. is a private company that designs and develops oncolytic virus vaccines. The company is based in New York, NY. The company was founded by David Schaffer, Douglas Hanahan, David H. Kirn, Theresa Janke, Melissa Kotterman. The CEO is Monika A. Vnuk. | Health Technology |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
